Mesothelioma | Tumor

CURE’s mesothelioma page is a go-to resource for oncology news and updates in the world of mesothelioma Here, readers will find cancer articles, videos, podcasts, and more with expert insight to the latest treatments and research in mesothelioma.

Expansion of IOA-244 Trial Fully Enrolled for Uveal Melanoma

November 26th 2021, 10:00pm

Article

Part B of the DIONE-01 study will look at whether IOA-244 increases anti-tumor responses in expansion groups of patients.

Imfinzi-Chemo Combo Improves Survival for Mesothelioma

November 16th 2021, 10:00pm

Article

Imfinzi plus platinum-pemetrexed chemotherapy induced survival improvements in patients with previously untreated, unresectable malignant pleural mesothelioma, compared with chemotherapy alone.

Opdivo May Improve Survival in Mesothelioma That Progressed on First-Line Chemotherapy

October 26th 2021, 3:00pm

Article

Treatment with the immunotherapy Opdivo for relapsed, malignant mesothelioma may represent a useful choice for patients with minimal therapy options.

COVID-19 Increases Death, Hospitalization Rates in Patients With Mesothelioma

September 20th 2021, 3:00pm

Article

The average survival for patients with malignant pleural mesothelioma was less than a month after being diagnosed with COVID-19, according to a small study.

Surgery After Radiotherapy May Improve Outcomes in Patients with Malignant Pleural Mesothelioma

August 26th 2021, 4:00pm

Article

Surgery for malignant pleural mesothelioma after radiotherapy may increase overall survival rates, according to a study. However, study authors note that the procedure should only be adopted in centers with substantial surgical experience.

Overcoming a Mesothelioma Diagnosis at a Young Age

April 12th 2021, 4:00pm

Article

Mesothelioma has been categorized as an “older persons” disease, writes a 14-year survivor. Which is why, she writes, her and her family were completely caught off-guard when she was diagnosed at 21.

FDA’s Approval of Opdivo-Yervoy for Unresectable Malignant Pleural Mesothelioma was ‘Desperately Needed’, But Questions Remain

October 20th 2020, 9:00pm

Article

The FDA’s approval or Opdivo (nivolumab) and Yervoy (ipilimumab) for the frontline treatment of patients with unresectable malignant pleural mesothelioma was desperately needed, says a thoracic oncologist at Memorial Sloan Kettering Cancer center. However, some questions remain.

FDA Approves Opdivo-Yervoy Combo for Unresectable Malignant Pleural Mesothelioma

October 2nd 2020, 8:42pm

Article

The Food and Drug Administration’s approval of Opdivo in combination with Yervoy for patients with unresectable malignant pleural mesothelioma marks the first new systemic therapy approved in more than 15 years in this setting.

CURE's Clinical Trial Corner: Mesothelioma Edition

November 25th 2019, 7:00pm

Article

Here is a list of clinical trials that are currently happening within the mesothelioma space.

Friday Frontline: Cancer Updates, Research and Education on November 22, 2019

November 22nd 2019, 9:00pm

Article

From plans to sue the School District of Philadelphia over a mesothelioma diagnosis to Dwayne “The Rock” Johnson singing for a 3-year-old with acute lymphoblastic leukemia, here’s what is making headlines in the cancer space this week.